- Home
- LEA vs NUVL Comparison
LEA vs NUVL Comparison
Compare LEA & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEA
- NUVL
- Stock Information
- Founded
- LEA 1917
- NUVL 2017
- Country
- LEA United States
- NUVL United States
- Employees
- LEA N/A
- NUVL N/A
- Industry
- LEA Auto Parts:O.E.M.
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- LEA Consumer Discretionary
- NUVL Health Care
- Exchange
- LEA Nasdaq
- NUVL Nasdaq
- Market Cap
- LEA 5.3B
- NUVL 5.6B
- IPO Year
- LEA N/A
- NUVL 2021
- Fundamental
- Price
- LEA $82.31
- NUVL $68.32
- Analyst Decision
- LEA Buy
- NUVL Strong Buy
- Analyst Count
- LEA 11
- NUVL 10
- Target Price
- LEA $126.09
- NUVL $113.10
- AVG Volume (30 Days)
- LEA 905.1K
- NUVL 588.4K
- Earning Date
- LEA 04-29-2025
- NUVL 05-08-2025
- Dividend Yield
- LEA 3.74%
- NUVL N/A
- EPS Growth
- LEA N/A
- NUVL N/A
- EPS
- LEA 8.97
- NUVL N/A
- Revenue
- LEA $23,306,000,000.00
- NUVL N/A
- Revenue This Year
- LEA N/A
- NUVL N/A
- Revenue Next Year
- LEA $3.65
- NUVL N/A
- P/E Ratio
- LEA $9.18
- NUVL N/A
- Revenue Growth
- LEA N/A
- NUVL N/A
- 52 Week Low
- LEA $81.43
- NUVL $61.80
- 52 Week High
- LEA $144.77
- NUVL $113.51
- Technical
- Relative Strength Index (RSI)
- LEA 29.69
- NUVL 35.51
- Support Level
- LEA $85.29
- NUVL $67.47
- Resistance Level
- LEA $89.88
- NUVL $77.93
- Average True Range (ATR)
- LEA 3.24
- NUVL 3.18
- MACD
- LEA -1.19
- NUVL -0.55
- Stochastic Oscillator
- LEA 5.39
- NUVL 10.23
About LEA Lear Corporation
Lear Corp designs, develops, and manufactures automotive seating and electrical systems and components. The company has two reporting segments Seating and E-Systems. Seating components include frames and mechanisms, covers (leather and woven fabric), seat heating and cooling, foam, and headrests. Automotive electrical distribution and connection systems and electronic systems include wiring harnesses, terminals and connectors, on-board battery chargers, high-voltage battery management systems. The company earns most of its revenue from the seating segment.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.